Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359097 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL28397725 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL259033 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL14748299 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL19585105 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL3137028 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2246998 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2251994 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL25787135 | 0.83 | TP53 (0.43) | TSHRTP53SLC7A5CYP2C9FPR1 | |
| Butyric Acid SCHEMBL16972049 | 0.82 | FFAR3 (0.52) | TSHRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110632227-B | Method for distinguishing Liuyang fermented soya beans, Yangjiang fermented soya beans and Yongchuan fermented soya beans | 中南林业科技大学 | 2022-03-18 | — | — | CN | claimed |
| US-12606850-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | Sasya, Inc. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12460234-B2 | Synthesis of isoprenoids and derivatives | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-11-04 | — | — | US | disclosed |
| US-12338481-B2 | Method for producing 2-methyl-butyric acid by bacterial fermentation | AJINOMOTO CO., INC. (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20250002949-A1 | SYNTHESIS OF BETA-HYDROXYISOVALERATE AND METHODS OF USE | Sasya Inc. | 2025-01-02 | — | — | US | disclosed |
| US-20240376483-A1 | RECOMBINANT MICROORGANISM AND L-LEUCINE PRODUCTION METHOD USING SAME | GREEN EARTH INSTITUTE CO., LTD. (JP) | 2024-11-14 | — | — | US | disclosed |
| US-20240182932-A1 | SYNTHESIS OF ISOPRENOIDS AND DERIVATIVES | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4034668-B1 | METHOD FOR PRODUCING 2-METHYL-BUTYRIC ACID BY BACTERIAL FERMENTATION | AJINOMOTO KK (JP) | 2024-04-17 | — | — | EP | disclosed |
| US-11920177-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | Sasya Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4320253-A1 | SYNTHESIS OF BETA-HYDROXYISOVALERATE AND METHODS OF USE | Sasya Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4034668-A1 | METHOD FOR PRODUCING 2-METHYL-BUTYRIC ACID BY BACTERIAL FERMENTATION | AJINOMOTO CO., INC. (JP) | 2022-08-03 | — | — | EP | disclosed |
| US-20220213515-A1 | METHOD FOR PRODUCING 2-METHYL-BUTYRIC ACID BY BACTERIAL FERMENTATION | AJINOMOTO CO., INC. (JP) | 2022-07-07 | — | — | US | disclosed |
| CN-110632227-B | Method for distinguishing Liuyang fermented soya beans, Yangjiang fermented soya beans and Yongchuan fermented soya beans | 中南林业科技大学 | 2022-03-18 | — | — | CN | disclosed |
| US-11046978-B2 | Synthesis of isoprenoids and derivatives | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021060337-A1 | METHOD FOR PRODUCING 2-METHYL-BUTYRIC ACID BY BACTERIAL FERMENTATION | AJINOMOTO CO., INC. (JP) | 2021-04-01 | — | — | WO | disclosed |
| US-20190352679-A1 | MICROBIAL SYNTHESIS OF ISOPRENOID PRECURSORS, ISOPRENOIDS AND DERIVATIVES INCLUDING PRENYLATED AROMATIC COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| US-9057063-B2 | Genetically modified biological cells | O'Keefe, Theresa (US) | 2015-06-16 | — | — | US | disclosed |
| US-8311790-B2 | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | UNIVERSITY OF DELAWARE (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100304432-A1 | GENETICALLY MODIFIED BIOLOGICAL CELLS | O'KEEFE, THERESA | 2010-12-02 | — | — | US | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606850-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | CYP51A1, CYP4Z1, CYP2U1 | TSHR 1764/4885TP53 1633/4885SLC7A5 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.